Driving Discovery: A Look Back at Admera Health's 2024
In 2024, Admera Health continued to push the boundaries of genomics research, delivering innovative solutions and elevating industry standards. By combining cutting-edge technology, scientific expertise, and unwavering dedication to quality, we empowered researchers to achieve their scientific goals.
This year, we focused on expanding our capabilities, strengthening our partnerships, and supporting our community of genomics researchers. Before 2024 comes to a close, let’s take a look back at Admera Health’s 2024 highlights.
Diving Deeper into RNA Discovery
RNA sequencing (RNA-seq) has revolutionized biological research, providing insights into gene expression, regulation, and disease mechanisms. In 2024, we continued to push the boundaries of transcriptomics research, providing innovative solutions.
We expanded our RNA-seq capabilities to include high-throughput bulk RNA-seq services, like DRUG-seq and BRB-seq. These technologies enable large-scale transcriptome studies at unprecedented scale and affordability, accelerating the pace of drug discovery and disease research.
To enable the identification of rare cell populations and better characterize cellular diversity, we’ve broadened our single-cell sequencing capabilities. By partnering with industry leaders like 10x Genomics, Parse Biosciences, and Singleron Biotechnologies, we provide a comprehensive suite of solutions tailored to diverse research needs. From difficult-to-sequence sample types to large-scale experiments, our services enable researchers to unlock the complexities of cellular heterogeneity with options that are best suited for their research needs.
We ventured further into the world of transcriptomics and expanded our offerings to support spatial transcriptomics studies with cutting-edge technology from leading providers like 10x Genomics and STOmics. Spatial transcriptomics technology allows researchers to analyze cells at single-cell resolution and study their spatial organization within tissues, providing invaluable insights into complex biological systems. Our spatial transcriptomics technology along with expertise from our scientists ensure we provide the right solutions for each unique project to study spatial biology with precision from a variety of sample types.
Our Commitment to Excellence
In 2024, we pushed the boundaries by elevating industry standards. We achieved Certified Service Provider Status with seven trusted partners. As a Certified Service Provider (CSP), we’ve earned the trust of both industry-leading vendors and our clients. This dual endorsement underscores our commitment to excellence and quality our clients can trust.
Furthering our commitment to excellence, we’ve introduced a new clinical-grade whole genome sequencing (cWGS) service. This rigorous service provides an additional layer of confidence for scientists seeking clinical-grade data.
Through delivering clinical-grade data and upholding certified provider status, we’re able to provide researchers with the highest quality services to advance their studies with confidence and piece of mind.
Expanding Horizons
This year, we’ve grown in more ways than one. We acquired German-based BioEcho Life Sciences, a premier provider of innovative nucleic acid extraction solutions. Combining BioEcho's innovative solutions with Admera Health's deep knowledge of working with complex sample types, we provide comprehensive NGS services of the highest quality. Read more about how Admera Health is expanding its capabilities through this strategic acquisition.
Supporting Researchers is at the Center of Everything We Do
Supporting researchers is at the center of everything we do. To accelerate discovery, we’ve launched two grant programs in 2024 to support researchers pursuing their single-cell sequencing and spatial transcriptomics projects. The grant programs sought to equip researchers with best-in-class tools from 10x Genomics and STOmics to uncover their complex biological questions with awards valued up to $13,000. We are thrilled to recognize David Christiani as a recipient of our single-cell grant program, enabling groundbreaking research into environmental impacts on lung and heart disease. We anticipate similar programs looking forward into 2025!
Making Meaningful Connections & Celebrating Milestones
2024 marked a decade of innovation and discovery at Admera Health. Over the past ten years, we’ve provided researchers with the best tools to succeed. A significant part of our success is due to the remarkable researchers we've had the privilege to collaborate with.
We believe that innovation thrives on connection. By fostering relationships with researchers from diverse backgrounds, we stay at the forefront of scientific advancements, learn about emerging technologies, and identify new ways to support your evolving research needs.
We're grateful for the opportunities to connect with researchers at events like AACR, FOG, ASHG, and many more. As we move into 2025, we look forward to deepening these relationships and exploring new ways to deliver superior NGS solutions.
We extend our gratitude to our dedicated team for their efforts in driving innovation and to our valued customers for your continued trust. Our commitment to providing the highest quality solutions remains steadfast and we look forward to all that we’ll accomplish together in 2025.